Compare Allstate Corp (ALL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs IDEXX Laboratories, Inc. — how do they compare? Allstate Corp trades at $257.61 (market cap $66.31B), while IDEXX Laboratories, Inc. trades at $571.64 (market cap $46.22B). The key difference: Allstate Corp is the larger of the two by market cap, and Allstate Corp pays a 1.65% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ALL | IDXX | |
|---|---|---|
Market Cap | $66.31B | $46.22B |
Sector | Financials | Health |
52-Week High | $275.11 | $766.68 |
52-Week Low | $190.00 | $526.44 |
Enterprise Value | $74.96B | $47.12B |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $256.62, down 4.84% over 24 hours, but maintains a bullish technical signal with strong fundamental performance. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. Recent news highlights institutional buying and positive analyst coverage, though some caution exists on sustainability.
The outlook remains positive with a consensus price target of $266.47, offering potential upside. Key risks include sustainability of underwriting margins and macroeconomic sensitivity. Earnings momentum and valuation metrics support a favorable investment case, but investors should monitor competitive pressures and catastrophe loss trends.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
